1. Cenci S, Mezghrani A, Cascio P, Bianchi G, Cerruti F, Fra A, Lelouard H, Masciarelli S, Mattioli L, Oliva L, Orsi A, Pasqualetto E, Pierre P, Ruffato E, Tagliavacca L, Sitia R. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. 2006;25(5):1104-13. PMID: 16498407.
2. Bianchi G*, Oliva L*, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, Palladini G, Giuliani N, Anderson KC, Sitia R, Cenci S. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113(13):3040-9. PMID: 19164601.
3. Chauhan D, Singh A, Brahmandam M, Carrasco R, Bandi, M, Hideshima, T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, Kumar SK, Richardson P, Munshi N, Anderson KC. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. (2009). Cancer Cell. 2009;16(4):309-23. PMID: 19800576.
4. Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Bianchi G, Mani M, Bandi M, Ikeda H, Perrone G, Hu Y, Tai YT, Zheng M, Cirstea D, Santo L, Carrasco D, Munshi N, Richardson P, Anderson KC. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010;115(25):5202-13. PMID: 20382844.
5. Bianchi G, Kyle RA, Colby CL, Larson DR, Kumar S, Katzmann JA, Dispenzieri A, Therneau TM, Cerhan J, L Melton III LJ, Rajkumar SV. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood. 2010;116(12):2019-25. PMID: 20495076. Chosen for CME activity by Blood.
6. Cenci S, Oliva L, Cerruti F, Milan E, Bianchi G, Raule M, Mezghrani A, Pasqualetto E, Sitia R, Cascio P. Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukoc Biol. 2012;92(5):921-31. PMID: 22685320.
7. Bianchi G, Kyle RA, Larson DR, Witzig TE, Kumar S, Dispenzieri A, Morice WG, Rajkumar SV. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013;27(3):680-5. PMID: 22902364.
8. Kikuchi S, Suzuki R, Ohguchi H, Yoshida Y, Lu D, Cottini F, Jakubikova J, Bianchi G, Harada T, Gorgun G, Tai YT, Richardson PG, Hideshima T, Anderson KC. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Leukemia. 2015;29(9):1918-27. PMID: 25801913.
9. Gorgun G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje NS, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman D, Richardson PG, Anderson KC. Lenalidomide Enhances Immune Checkpoint Blockade Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015;21(20):4607-18. PMID: 25979485.
10. Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 2018;32(4):996-1002. PMID: 29158558.
11. Guo G, Raje N, Seifer C, Kloeber K, Isenhart R, Ha G, Yee A, O’Donnell E, Tai YT, Richardson P, Bianchi G, Laubach J, Warren D, Gemme E, Voisine J, Frede J, Kokkalis A, Yun H, Dimitrova V, Vijaykumar T, Meyerson M, Munshi N, Anderson K, Knoechel B, Lohr J. Genomic discovery and clonal tracking in multiple myeloma by cell free DNA sequencing. Leukemia. 2018;32(8):1838-1841. PMID: 29749395.
12. Ehman EC, El-Sady MS, Kijewski MF, Khor YM, Jacob S, Ruberg FL, Sanchorawala V, Landau H, Yee AJ, Bianchi G, Di Carli MF, Falk RH, Hyun H, Dorbala S. Early Detection of Multiorgan Light Chain (AL) Amyloidosis by Whole Body 18F-florbetapir PET/CT. J Nucl Med. 2019;60(9):1234-1239. PMID: 30954943.
13. Ho M**, Chen T, Liu J, Dowling P, Hideshima T, Zhang L, Morelli E, Camci-Unal G, Wu X, Tai YT, Wen K, Samur M, Schlossman RL, Mazitschek R, Kavanagh EL, Lindsay S, Harada T, McCann A, Anderson KC*, O’Gorman P*, Bianchi G*. Targeting Histone Deacetylase 3 (HDAC3) in the Bone Marrow Microenvironment Inhibits Multiple Myeloma Proliferation by Modulating Exosomes and IL-6 Trans-Signaling. Leukemia. 2020;34(1):196-209. PMID: 31142847.
14. Khor YM, Cuddy S, Harms HJ, Kijewski MF, Park MA, Robertson M, Hyun H, Di Carli MF, Bianchi G, Landau H, Yee AJ, Sanchorawala V, Frederick L. Ruberg FL, Liao RL, Berk J, Falk RH, Dorbala S. Quantitative [18F]florbetapir PET/CT May Identify Lung Involvement in Patients with Systemic AL Amyloidosis. Eur J Nucl Med Mol Imaging. 2020;47(8):1998-2009. PMID: 31807884.
15. Xu Y, Fulciniti M, Samur MK, Ho M, Deng S, Liu L, Wen K, Yu T, Chyra Z, Dereibal S, Zhang L, Yao Y, Chakraborty C, Morelli E, Li N, Lopez MA, Perini T, Mu S, An G, Alonso R, Bianchi G, Anderson KC, Qiu L, and Munshi NC. YWHAE/14-3-3ε expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020;136(4):468-479. PMID: 32187357.
16. Cuddy S, Bravo PE, Falk RH, El-Sady S, Kijewski MF, Park M-A, Ruberg FL, Sanchorawala V, Landau H, Yee AJ, Bianchi G, Di Carli MF, Cheng S-C, Jerosch-Herold M, Kwong RY, Liao R, Dorbala S. Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease? JACC Cardiovasc Imaging. 2020;13(6):1325-2336. PMID: 32417333.
17. Liu J, Hideshima T, Xing, Wang S, Zhou W, Samur MK, Sewastianik T, Ogiya D, An G, Gao S, Yang L, Ji T, Bianchi G, Wen K, Tai YT, Munshi N, Richardson P, Carrasco R, Cang Y and Anderson KC. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021 Jun 4;7(23):eabg2697. PMID: 34088671.
18. Bianchi G, Czarnecki PG, Ho M, Roccaro AM, Sacco A, Kawano Y, Gullà A, Aktas Samur A, Chen T, Wen K, Tai YT, Moscvin M, Wu X, Camci-Unal G, Da Vià MC, Bolli N, Sewastianik T, Carrasco RD, Ghobrial IM and Anderson KC. ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer Discov. 2021 Jul;2(4):338-353. PMID: 34268498.
19. Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 Sep;2(5):468-483. PMID: 34568832
20. Sacco A, Federico C, Todoerti K, Ziccheddu B, Palermo V, Giacomini A, Ravelli C, Maccarinelli F, Bianchi G, Belotti A, Ribolla R, Favasuli V, Revenko AS, MacLeod RA, Willis BS, Cai H, Hauser J, Rooney C, Willis SE, Martin PL, Staniszewska AD, Ambrose H, Hanson L, Cattaneo C, Tucci A, Rossi G, Ronca R, Neri A, Mitola S, Bolli N, Presta M, Moschetta M, Ross S, Roccaro AM. Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited anti-tumor activity. Blood. 2021 Nov 4;138(18):1705-1720. PMID: 34077955.
21. Usmani SZ, Karanes C, Bensinger WI, D’Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021 Dec;35(12):3526-3533. PMID: 34050260.
22. Chen T**, Ho M, Briere J, Moscvin M, Czarnecki PG, Anderson KC, Blackwell TK, Bianchi G. Multiple Myeloma Cells Depend on the DDI2/NRF1-mediated Proteasome Stress Response for Survival. Blood Adv. 2022 Jan 25;6(2):429-440. PMID: 34649278.
23. Cuddy SAM, Jerosch-Herold M, Falk RH, Kijewski MF, Singh V, Ruberg FL, Sanchorawala V, Landau H, Maurer MS, Yee AJ, Bianchi G, Di Carli MF, Liao R, Kwong RY, Dorbala S. Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC Cardiovasc Imaging. 2022 Apr;15(4):594-603. PMID: 34922860.
24. Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, Bianchi G, Guo G, Potdar S, Seifer C, Nair MS, Kokkalis A, Kloeber JA, Shapiro S, Budano L, Mann M, Friedman R, Lipe B, Campagnaro E, O’Donnell EK, Zhang CZ, Laubach JP, Munshi NC, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG. Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia. 2022 Apr;36(4):1078-1087. PMID: 35027656.
25. O’Gorman P, Laubach JP, O’Dwyer ME, Krawczyk J, Yee AJ, Gilligan O, Cahill MR, Rosenblatt J, Quinn J, Murphy PT, DiPietro H, Perera MR, Crotty GM, Cummings K, Hayden PJ, Browne P, Savell A, O’Leary HM, O’Keeffe D, Masone K, Hennessy BJ, Guerrero Garcia T, Scott K, Saeed K, Bianchi G, Dowling P, Tierney C, Richardson PG. Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. Am J Hematol. 2022 May;97(5):562-573. PMID: 35132679.
26. Ho M, Moscvin M, Low SK, Evans B, Close S, Schlossman R, Laubach J, Paba Prada C, Glotzbecker B, Richardson PG, Bianchi G. Risk Factors for the Development of Orthostatic Hypotension During Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Leukemia and Lymphoma. 2022 Jun 14;1-10. PMID: 35699975.
27. Bianchi F*#, Bianchi G*#, Song D*#. The Long-Term Impact of the COVID-19 Unemployment Shock on Life Expectancy and Mortality Rates. J of Economic Dynamics and Control. 2022 Dec 5. DOI: https://doi.org/10.1016/j.jedc.2022.104581.
28. Moscvin M**, Liacos CI, Chen T, Theodorakakou F, Fotiou D, Hossain S, Rowell S, Leblebjian H, Regan E, Czarnecki P, Bagnoli F, Bolli N, Richardson P, Rennke HG, Dimopoulos MA, Kastritis E, Bianchi G#. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. Blood Cancer J. 2023 Feb 27;13(1):31. PMID: 36849497.
29. Estiverne, C, McMahon, GM, Mount D, Bianchi G, Rennke, HG, Daddio Pierce C, Hakim H, Czarnecki, PG. Safety and Diagnostic Yield of Protocolized Percutaneous Kidney Biopsies in Mechanically Ventilated Patients with Acute Kidney Injury. Kidney International Reports. 2023 June; 8(6):1255-1259. PMID: 37284670
30. Morelli E, Fulciniti M, Samur MK, Ribeiro CF, Wert-Lamas L, Henninger JE, Gulla A, Aktas-Samur A, Todoerti K, Talluri S, Park WD, Federico C, Scionti F, Amodio N, Bianchi G, Johnstone M, Liu N, Gramegna D, Maisano D, Russo NA, Lin C, Tai YT, Neri A, Chauhan D, Hideshima T, Shammas MA, Tassone P, Gryaznov S, Young RA, Anderson KC, Novina CD, Loda M, Munshi NC. MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth. Blood. 2023 Jan; 141(4):391-405. PMID: 36126301
31. Liu X*, Moscvin M*/**, Oh S, Chen T, Choi W, Evans B, Rowell SM, Nadeem O, Mo CC, Sperling AS, Anderson KC, Yaqoob Z, Bianchi G*#, Sung Y*#. Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs. Clinic Exp Med. 2023 Jul 8. PMID: 37421589.
32. Clerc OF, Cuddy SAM, Robertson M, Vijayakumar S, Neri JC, Chemburkar V, Kijewski MF, Di Carli MF, Bianchi G, Falk RH, Dorbala S. Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir: A Pilot PET/CT Study. JACC Cardiovasc Imaging. 2023 Nov;16(11):1419-1432. PMID: 37676210.
33. Datar Y, Clerc OF, Cuddy SAM, Kim S, Taylor A, Neri JC, Benz DC, Bianchi G, Yee AJ, Sanchorawala V, Ruberg FL, Landau H, Liao R, Kijewski MF, Jerosch-Herold M, Kwong RY, Di Carli MF, Falk RH, Dorbala S. Quantification of right ventricular amyloid burden with 18F-florbetapir positron emission tomography/computed tomography and its association with right ventricular dysfunction and outcomes in light-chain amyloidosis. Eur Heart J Cardiovasc Imaging. 2024 Apr 30;25(5):687-697. PMID: 38193678.
34. Lopedote P**, Evans B, Marchetti A, Chen T, Moscvin M, Boullt S, Bolli N, Bianchi G#. Clonal Hematopoiesis of Indeterminate Potential in Patients with Immunoglobulin Light Chain AL Amyloidosis. Blood Advances. 2024 Jul 9;8(13):3427-3436. PMID: 38652890.
35. Clerc OF, Vijayakumar S, Cuddy SAM, Bianchi G, Canseco Neri J, Taylor A, Benz DC, Datar Y, Kijewski MF, Yee AJ, Ruberg FL, Liao R, Falk RH, Sanchorawala V, Dorbala S. Functional Status and Quality of Life in Light-Chain Amyloidosis: Advanced Imaging, Longitudinal Changes, and Outcomes. JACC Heart Fail. 2024 Aug 20:S2213-1779(24)00562-6. PMID: 39243245.
36. Clerc OF, Cuddy SAM, Jerosch-Herold M, Benz DC, Katznelson E, Canseco Neri J, Taylor A, Kijewski MF, Bianchi G, Ruberg FL, Di Carli MF, Liao R, Kwong RY, Falk RH, Dorbala S. Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis. JACC Cardiovasc Imaging. 2024 Jul 1:S1936-878X(24)00193-1. PMID: 39001736.
37. Clerc OF, Datar Y, Cuddy SAM, Bianchi G, Taylor A, Benz DC, Robertson M, Kijewski MF, Jerosch-Herold M, Kwong RY, Ruberg FL, Liao R, Di Carli MF, Falk RH, Dorbala S. Prognostic Value of Left Ventricular 18F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis. JACC Cardiovasc Imaging. 2024 Aug;17(8):911-922. PMID: 3900173.
38. Li H, Côté P, Kuoch M, Ezike, J, Frenis K, Afanassiev A, Greenstreet L, Tanaka-Yano M, Tarantino G, Zhang S, Whangbo J, Butty VL, Moiso E, Falchetti M, Lu K, Connelly GG, Morris V, Wang D, Chen AF, Bianchi G, Daley GQ, Garg S, Liu D, Chou ST, Regev A, Lummertz da Rocha E, Schiebinger G, Rowe RG. The dynamics of hematopoiesis over the human lifespan. Nat Methods. 2025 Feb;22(2):422-434. doi: 10.1038/s41592-024-02495-0. Epub 2024 Dec 5. PMID: 39639169; PMCID: PMC11908799.
39. Yee AJ, Laubach JP, Campagnaro EL, Lipe BC, Nadeem O, Friedman RS, Cole CE, O’Donnell E, Bianchi G, Branagan AR, Schlossman RL, Shaprio SJ, Harrington CC, Burke JN, Gammon MT, Lively KJ, Reimonn CA, Andrade DX, Redd RA, Lohr JG, Anderson KC, Richardson PG, Raje N. Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. Blood Adv. 2025 Mar 11;9(5):1163-1170. doi: 10.1182/bloodadvances.2024014717. PMID: 39626297; PMCID: PMC11925518.
40. Saunders B*/**, Theodorakakou F*, Fotiu, D, Boullt S, Evans B, Dimopoulos MA, Kastritis E*#, Bianchi, G*#. Predictive Value of Free Light Chain Burden in Patients Newly Diagnosed with AL Amyloidosis Treated with Bortezomib and Daratumumab-Based Regimens. Blood Adv. Epub. 2025 Apr 30;. doi: 10.1182/bloodadvances.2024015528. PMID: 40305663.
41. Gort-Freitas NA**, Moscvin M, Da Vià MC, Lazzaroni F, Nevone A, Sadigh S, Boullt S, Evans B, Chen T, Karagiannis T, Tai A, Rowell S, Raghav S, Chen AF, Laubach JP, Edwards C, Aster JC, Sheng Z, Paulo, Chan CN, Nuvolone M, Bolli N, Comenzo RL, Klein AM*#, Bianchi G*#. Single cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment. Accepted, Blood.
42. Vianna P**, Chakraborty R, Bhutani D, Hossain S, Miller S, Rossi A, Cuddy SAM, Falk RH, Lentzsch S, Laubach JL, Bianchi G#. Safety and Efficacy of Elranatamab in Patients with Daratumumab Relapsed and/or Refractory Immunoglobulin Light Chain Amyloidosis. Resubmitted after revisions, Blood.
1. Chauhan D, Bianchi G, Anderson KC. Targeting the UPS as therapy in multiple myeloma. BMC Biochem. 2008;9 Suppl 1:S1. PMID: 19007431.
2. Bianchi G, Qin D, Dearani JA, Qi Q. Near-fatal infection following an elective ankle-fracture fixation: less risk should not mean less vigilance. Chin Med J (Engl). 2011;124(12):1911-4. PMID: 21740853.
3. Bianchi G, Ghobrial IM. Does my patient with a serum monoclonal spike have multiple myeloma? Hematol Oncol Clin North Am. 2012;26(2):383-93, ix. PMID: 22463833.
4. Bianchi G, Kumar S, Ghobrial IM, Roccaro AM. Cell Trafficking in Multiple Myeloma. Open J Hematol. 2012;3(Suppl 1). PMID: 23762527.
5. Bianchi G, Ghobrial IM. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. Leuk Lymphoma. 2013;54(2):229-41. PMID: 22897729.
6. Bianchi G, Sacco A, Kumar S, Rossi G, Ghobrial I, Roccaro A. Candidate genes of Waldenstrom’s macroglobulinemia: current evidence and research. Appl Clin Genet. 2013;6:33-42. PMID: 23935380.
7. Bianchi G, Anderson KC, Harris NL, Sohani AR. The heavy chain diseases: clinical and pathologic features. Oncology (Williston Park). 2014;28(1):45-53. PMID: 24683718.
8. Bianchi G, Richardson PG, Anderson KC. Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014;32(20):2125-32. PMID: 24888801.
9. Bianchi G, Anderson KC. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014;64(6):422-44. PMID: 25266555.
10. Bianchi G, Ghobrial IM. Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. Curr Cancer Ther Rev. 2014;10(2):70-79. PMID: 25705146.
11. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015; 125(20):3049-58. PMID: 25838343.
12. Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood. 2015;126(3):300-10. PMID: 26031917.
13. Manier S, Kawano Y, Bianchi G, Roccaro AM, Ghobrial IM. Cell autonomous and micro-environmental regulation of tumor progression in precursor states of Multiple Myeloma. Curr Opin Hematol. 2016;23(4):426-33. PMID: 27101529.
14. Ho M**, Bianchi G. Targeting Protein Synthesis and Degradation in Multiple Myeloma: A Look at What’s on the Horizon. Am J Hematol Oncol. 2017;13(3):4-14.
15. Bianchi G, Sohani AR. Heavy Chain Disease of the Small Bowel. Curr Gastroenterol Rep. 2018;20(1):3. PMID: 29372346.
16. Ho M**, McCann A*, Bianchi G*, Zhang L, Dowling P, Despina B, O’Gorman P, Anderson KC. Overcoming Multiple Myeloma Drug Resistance in the Era of Cancer “Omics”. Leuk Lymphoma. 2018;59(3):542-561. PMID: 28610537.
17. Ho M*/**, Patel A*, Hanley C, Murphy A, McSweeney T, Zhang L, McCann A, O’Gorman P, Bianchi G. Exploiting Autophagy in Multiple Myeloma. J Cancer Metastasis Treat. 2019;5:70. DOI: 10.20517/2394-4722.2019.25
18. Ho M**, Kavanagh EL, Dunne LP, Dowling P, Zhang L, Lindsay S, Bazou D, Goh CY, Hanley C, Bianchi G, Anderson KC, O’Gorman P, McCann A. Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. Cancers (Basel). 2019 Jan 9;11(1). PMID: 30634515.
19. Bianchi G, Anderson KC. Contribution of Inhibition of Protein Catabolism in Myeloma. Cancer J. 2019;25(1):11-18. PMID: 30694855.
20. Ho M**, Bianchi G, Anderson KC. Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Review of Precision Medicine and Drug Development. 5(2):67-85. PMID: 34414281.
21. Ho M**, Goh CY, Patel A, Staunton S, O’Connor R, Godeau M, Bianchi G. Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. Clinical Lymphoma Myeloma Leukemia. 2020;20(10):e752-e768. PMID: 32651110.
22. Chen T**, Moscvin M, Bianchi G. Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment. Front Oncol. 2020;10:608815. PMID: 33251153.
23. Ho M**, Patel A, Goh CY, Moscvin M, Zhang L, Bianchi G. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia. 2020;34(12):3111-3125. PMID: 33046818.
24. Bianchi G, Kumar S. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases. Hematol Oncol Clin North Am. 2020;34(6):1009-1026. PMID: 33099420.
24. Murray D, Puig N, Kristinsson S, Usmani S, Dispenzieri A, Chng WJ, Bianchi G, Kumar S, Hajek R, Paiva B, Waage A, Rajkumar S, Durie B. Mass Spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: An International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021 Feb 1;11(2):24. PMID: 33563895.
25. Murray D, Puig N, Kristinsson S, Usmani S, Dispenzieri A, Chng WJ, Bianchi G, Kumar S, Hajek R, Paiva B, Waage A, Rajkumar S, Durie B. Mass Spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: An International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021 Feb 1;11(2):24. PMID: 33563895.
26. Blum A, Bazou D, Ting KR, Bianchi G, Mahandran M, Mahandran H, Eustace S, Richardson PG, O’Gorman P. Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation – a case series. Br J Haematol. 2021 May;193(4):e36-e38. PMID: 33748981.
27. Bianchi G, Zhang Y, Comenzo RL. AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies. JACC CardioOncol. 2021 Oct 19;3(4):467-487. PMID: 34729520.
28. Moscvin M, Ho M, Bianchi G. Overcoming drug resistance by targeting protein homeostasis in multiple myeloma. Cancer Drug Resist 2021;4:1027-45. PMID: 35265794.
29. Bianchi G, Moscvin M, Comenzo RL. Laboratory-Based Rationale for Targeting the Protein Homeostasis Network in AL Amyloidosis. Hemato 2022, 3(2), 298-317 (Special Issue “Advances in Amyloidosis: A Theme Issue in Honor of Prof. Dr. Giampaolo Merlini”).’
30. Ho M**, Xiao A, Yi D, Zanwar S, Bianchi G#. Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment. Curr Oncol. 2022 Nov 21;29(11):8975-900. PMID: 36421358.
31. Moscvin M**, Evans B, Bianchi G#. Dissecting Molecular Mechanisms of Immune Microenvironment Dysfunction in Multiple Myeloma and Precursor Conditions. J of Cancer Metastasis and Treatment. 2023;9:17. PMID: 38213954.
32. Mo CC, Yee AJ, Midha S, Hartley-Brown MA, Nadeem O, O’Donnell EK, Bianchi G, Sperling AS, Laubach JP, Richardson PG. Selinexor: Targeting a novel pathway in multiple myeloma. 2023 May 15;4(3):792-810. PMID: 37601856.
33.Midha S, Hartley-Brown MA, Mo CC, Hossain S, Nadeem O, O’Donnell EK, Bianchi G, Sperling AS, Laubach JP, Richardson PG. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma. Expert Opin Drug Saf. 2023 Jul-Dec;22(11):1049-1071. PMID: 37906232.
34. Liu Y, Mo CC, Hartley-Brown MA, Sperling AS, Midha S, Yee AJ, Bianchi G, Piper C, Tattersall A, Nadeem O, Laubach JP, Richardson PG. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. Expert Rev Hematol. 2024 Aug;17(8):445-465. PMID: 39054911.
35. Chowdhury RB**/#, Shah SI, Milford E, Tullius SG, Rennke H, Bianchi G#. Extramedullary plasmacytoma exclusively localized in transplanted kidney: Post-transplant lymphoproliferative disorder or monoclonal gammopathy of renal significance? Journal of Onco-Nephrology. 2024;8(2):70-74.
36. Bart NK, Bianchi G, Cuddy SAM, Goyal P, Griffin JM, Hummel SL, Macdonald P, Maurer M, Montgomery E, Nanne MG, Orkaby AR, Sanchorawala V, Damluji, AA. Amyloidosis in Older Adults with A Focus on Frailty: JACC Advances Expert On behalf of the ACC Geriatric Cardiology Leadership Council. JACC Adv. 2025 May 14;4(6 Pt 1):101784.